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Abstract
Background: The metabolic syndrome (MetS) is an established cardiovascular risk factor. Here, we investigated its
role in cognitive impairment.
Methods: Baseline data from 202 participants (aged 65 to 87 years) of the BioCog study were used. All were free of
clinical dementia (MMSE≥24/30). Cognitive impairment was defined as the lowest tertile of a cognitive summary score.
Multiple logistic regression analyses examined associations of body mass index (BMI), triglycerides (TG), high-density
lipoprotein (HDL-C), glucose and glycated hemoglobin A1c (HbA1c) levels with the odds of cognitive impairment.
MetS was defined as ≥3 of its 5 components obesity (BMI≥ 30 kg/m2), elevated TG (TG ≥1.7 mmol/L), reduced HDL-C
(males: < 1.0 mmol/L; females: < 1.3 mmol/L), elevated glucose (glucose ≥5.5 mmol/L and/or diagnosed diabetes) and
elevated blood pressure (history of hypertension). Analyses controlled for age, sex and smoking history.
Results: Lower HDL-C was significantly associated with a higher odds of cognitive impairment (OR 2.70 per 1 mmol/L
reduction; 95% CI 1.25, 5.56; p = 0.011), whereas BMI, TG, glucose and HbA1c were not (all p > 0.05). Results for HDL-C
were similar when HDL-C, glucose, BMI and TG were entered into a single model (OR 2.56 per 1 mmol/L reduction,
95% CI 1.09, 5.88, p = 0.031) and when cerebrovascular disease and coronary heart disease were additionally controlled
for (OR 2.56 per 1 mmol/L reduction, 95% CI 1.06, 6.25, p = 0.036). Among the 5 MetS components, participants with
elevated TG were at 2-fold increased odds of impairment (OR 2.09, 95% CI 1.08, 4.05, p = 0.028) including when the
remaining 4 MetS components were entered (OR 2.23, 95% CI 1.07, 4.65, p = 0.033), but the finding was no longer
statistically significant when cerebrovascular disease and coronary heart disease were additionally controlled for
(p = 0.11). Presence of MetS and of obesity, reduced HDL-C, elevated glucose or elevated blood pressure were
not significantly associated with impairment (all p > 0.05).
Conclusion: Our findings support low HDL-C as an independent risk marker of cognitive impairment in older
age. The need for research into mediatory and confounding factors, and re-evaluation of traditional cut-off points
is highlighted.
Trial registration: The study was registered on 15th October 2014 at clinicaltrials.gov (NCT02265263).
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Background
The metabolic syndrome (MetS) is a cluster of metabolic
abnormalities, including abdominal obesity, elevated
blood pressure (BP), elevated blood glucose levels, low
high-density lipoprotein cholesterol (HDL-C) levels, and
elevated triglyceride (TG) levels, and is suggested to play
a major role in the development of cardiovascular dis-
ease (CVD) and type 2 diabetes mellitus [1]. Although
its definition had been a matter of debate [1], MetS is
now a widely accepted concept [2], and has been used
across multiple populations to assess cardiovascular and
mortality risk [3]. For example, it was estimated that 11
million deaths world-wide can be attributed to MetS an-
nually [3]. Although MetS has traditionally primarily
been linked to CVD, studies suggest that MetS [4–7]
and metabolic abnormalities more generally [7–9] may
also be related to cognitive impairment as a type of
organ dysfunction that burdens the global economy to
extents similar to CVD [10]. Chronically elevated blood
glucose levels, for instance, have consistently been asso-
ciated with an increased risk of future cognitive impair-
ment [11].
MetS [12] and its contributing parameters of meta-
bolic dysfunction (e.g., [13]) are hugely prevalent in
Western societies and on a global scale, but all are modi-
fiable. This implies a potential for strategic improvement
of public health that warrants clarification. We therefore
examined associations of MetS, of each of its 5 compo-
nents and of associated continuous parameters of meta-
bolic dysfunction with cognitive impairment in a
community-based sample of older adults without clinical
dementia.
Method
Study design
We analyzed cross-sectional associations of MetS with
cognitive impairment in the Biomarker Development for
Postoperative Cognitive Impairment in the Elderly (Bio-
Cog) study (http://www.biocog.eu). The primary aim of
the study is to identify biomarkers predictive of post-op-
erative cognitive impairment in patients undergoing
elective surgery at study sites in Utrecht, the
Netherlands, and Berlin, Germany. Details on recruit-
ment procedures and study protocol have been reported
elsewhere [14] and the study was registered on 15th Oc-
tober 2014 at clinicaltrials.gov (NCT02265263). In brief,
patients were eligible to participate if they were aged
≥65 years, Caucasian, scheduled for elective surgery of
any type with operative time ≥ 60min and with an ex-
pected post-operative hospital treatment period of at
least 7 days, and if they scored normal on a screening
tool for dementia (Mini Mental State Examination,
MMSE≥24/30). Of 7727 patients screened for inclusion,
933 were recruited between November 2014 and April
2017. Here, we report on baseline metabolic and cogni-
tive data that were collected before surgery from the first
400 of those patients. Participants with missing data on
any of the 5 MetS components or any missing cognitive
data were excluded from our analysis.
Clinical interview and physical examination
Participants self-reported on smoking history and socio-
demographic parameters. Arterial hypertension, diabetes,
a history of transient ischemic attacks (TIA), a history of
stroke and coronary heart disease (CHD) were ascer-
tained from a combination of self-report and local hos-
pital records on pre-existing conditions and medication.
Weight and height were measured to calculate body
mass index (BMI).
Biomarker measurement
Blood was collected immediately before induction of
anesthesia in a supine position and following an over-
night fast. HbA1c was measured in a laboratory adjacent
to the respective hospital site. Blood was additionally
centrifuged and serum samples stored at − 80 °C for
shipment to a central biobank repository. Samples were
later retrieved from that biobank for measurement of
glucose, TG and HDL-C levels. Those analyses were per-
formed at a single laboratory. Because samples stored at
the biobank were insufficient for N = 16 participants of
our analysis sample, data on glucose, TG and HDL-C
were used from the immediate laboratory adjacent to
the hospital site for those 16 participants. Sensitivity
analyses revealed no influence of analysis laboratory on
any of the results reported here (data not shown). For
one participant, blood was collected after induction of
anesthesia but before incision. Their data were not
excluded.
Definition of metabolic syndrome
In accordance with standardized criteria [15], we used a
slightly modified definition of MetS (Table 1). BMI was
used to define obesity instead of waist circumference,
since waist circumference was not measured in our study.
Cognitive examination
Participants underwent neuropsychological testing in a
quiet hospital room usually on the day before surgery.
The MMSE was used to screen for clinical dementia for
inclusion into the study, before a series of computer-based
(Cambridge Neuropsychological Test Automated Battery,
CANTAB®; Cambridge Cognition Ltd.) and paper-pencil
tests were performed: Paired Associates Learning (PAL),
Verbal Recognition Memory (VRM), Spatial Span
(SSP), Simple Reaction Time (SRT), Trail-Making
Test-B (TMT-B), and Grooved Pegboard (GP). Principal
component analysis (PCA) with extraction of factors with
Feinkohl et al. BMC Geriatrics           (2019) 19:77 Page 2 of 11
Eigenvalue > 1 was applied to the 6 cognitive tests to de-
rive a score of global cognitive ability (‘g’) [16]. G is un-
affected by test-specific measurement error, produces
more reliable results compared with individual cognitive
tests and typically accounts for around 40% of variance
[17]. G is independent of cognitive test battery [18], and
all aforementioned tests have been used to calculate g in
the past (e.g., [18]). Visual inspection of a scree plot con-
firmed presence of a single factor (Eigenvalue 2.37)
explaining 39.53% of variance in the data. Standardized re-
siduals of that factor were saved to obtain an operant la-
tent variable g (factor loadings TMT-B, 0.77; PAL, 0.71;
GP, 0.67; VRM, 0.56; SSP, 0.54; SRT, 0.49). ‘Cognitive im-
pairment’ was defined as scoring in the lowest tertile of g
and was the outcome of interest in our analysis. As a
screening tool for dementia [19], the MMSE was not used
to calculate g.
Statistical analysis
Data for MMSE, TMT-B, SRT and GP were log trans-
formed prior to analysis to approximate normal distribu-
tion. An initial univariate analysis of variance (ANOVA)
compared MMSE scores across tertiles of g; a chi2 test
compared associations of MMSE< 27 (indicative of pro-
dromal dementia) with presence of cognitive impairment.
Participants were divided into quartiles based on the
respective distributions of HbA1c, glucose, TG, HDL-C
and BMI. We then used multiple logistic regression to
examine the association of each with odds of cognitive
impairment using the lowest quartile as the reference
category. In addition, we used each on a continuous
scale. For each analysis, we ran three regression models:
Model 1 was adjusted for age, sex and smoking. Model 2
included age, sex, smoking, BMI, TG, HDL-C, and either
glucose or HbA1c. Model 3 additionally included CHD,
TIA and stroke. To check for non-linearity in the
association with cognitive impairment, we subsequently
added quadratic terms into the respective final model
(Model 3).
We next categorized MetS and each of its components
based on established definitions (Table 1) and studied
their association with odds of cognitive impairment using
multiple logistic regression. Again, Model 1 was adjusted
for age, sex and smoking, Model 2 included age, sex,
smoking and all 5 MetS components, and Model 3 add-
itionally controlled for CHD, TIA and stroke.
We then studied the association of the number of
abnormal MetS components with the odds of cogni-
tive impairment using 0 abnormal components as ref-
erence category. For the purpose of this analysis, the
groups with 4 or 5 components were merged due to
small participant numbers in these groups. Finally,
the number of MetS components (range 0 to 5) was
entered into a multiple logistic regression model. For
these analyses, Model 1 controlled for age, sex and
smoking, and Model 2 additionally controlled for
CHD, TIA and stroke. All results remained un-
changed following exclusion of 2 underweight partici-
pants (BMI ≤ 18.5 kg/m2) and 1 participant with very
high TG (28.9 mmol/L) in a separate analysis unless
stated otherwise. SPSS version 18.0 (IBM Corporation,
New York) was used.
Results
Sample characteristics
A total of 202 participants enrolled into the study had
complete cognitive and MetS data. Demographic, meta-
bolic and cognitive characterization of the analysis sam-
ple is shown in Table 2. Participants were most
commonly scheduled for orthopedic, gynecologic/uro-
logic or general surgery and a majority had elevated BP
Table 1 Definition of metabolic syndromea
Component Standard criteriab Criteria used in present study
Elevated waist
circumference
Population- and country-specific definitions BMI≥ 30 kg/m2
Elevated TG TG ≥ 150mg/dL (1.7 mmol/L), or drug treatment Fasting TG ≥150mg/dl (1.7 mmol/L)
Reduced HDL-C HDL-C < 40 mg/dL (1.0 mmol/L) in males; HDL-C < 50 mg/dl
(1.3 mmol/L) in females; or drug treatment
HDL-C < 40 mg/dl (1.0 mmol/L) in males
HDL-C < 50 mg/dl (1.3 mmol/L) in females
Elevated
blood pressure
Systolic ≥130 and/or diastolic ≥85 mmHg, or drug treatment Hypertension based on self-report and/or local
hospital records
Elevated glucose ≥100mg/dL in plasma, or drug treatment 1. Fasting blood glucosec ≥100mg/dL (5.5 mmol/L)
(if not fasted, HbA1c ≥42 mmol/mold)
and/or
2. Diabetes based on self-report and/or local hospital records
aThe metabolic syndrome is defined as the presence of at least 3 of the 5 components
bConsensus statement [15]
cGlucose measured in serum (nearly identical to plasma; [59])
dIn the present sample, all participants were fasted
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Table 2 Demographic, metabolic and cognitive sample characteristics
Means ± SD, median (interquartile range)
or n of total N = 202 analysis sample
% of N
Study site
UMC Utrecht, n (%) 33 16.3%
Charité Berlin Campus Virchow, n (%) 114 56.4%
Charité Berlin Campus Mitte, n (%) 55 27.2%
Male, n (%) 121 59.9%
Age, years, mean ± SD 72.12 ± 4.74
Smoking history, n (%)
Missing 28 13.9%
Never smokers 54 26.7%
Former smokers 93 46.0%
Current smokers 27 13.4%
History of coronary heart disease, n (%) 28 13.9%
History of stroke, n (%) 9 4.5%
History of transient ischemic attack, n (%) 6 3.0%
History of diabetes, n (%) 39 19.3%
Non-insulin dependent diabetes, n (%) 23 11.4%
Insulin-dependent diabetes, n (%) 16 7.9%
History of dyslipidemia, n (%) 40 19.8%
Body mass index (BMI; kg/m2), mean ± SD 27.12 ± 4.39
Serum glucose (mmol/L), median (interquartile range) 5.77 (5.27–6.49)
HbA1ca (mmol/mol), mean ± SD 39.68 ± 8.20
Triglycerides (TG) (mmol/L), median (interquartile range) 1.31 (1.04–1.79)
Total cholesterola (mmol/L), mean ± SD 4.88 ± 1.12
Low-density lipoproteina (LDL-C) (mmol/L), mean ± SD 3.11 ± 0.98
High-density lipoprotein (HDL-C) (mmol/L), mean ± SD 1.27 ± 0.43
BMI categories, n (%)
Underweight (BMI ≤ 18.5 kg/m2), n (%) 2 1.0%
Normal/overweight (BMI 18.6–29.9 kg/m2), n (%) 155 76.7%
Obesity (BMI ≥30 kg/m2), n (%) 45 22.3%
Elevated blood pressureb, n (%) 123 60.9%
Elevated fasting glucoseb, n (%) 125 61.9%
Elevated TGb, n (%) 60 29.7%
Reduced HDL-Cb, n (%) 69 34.2%
Metabolic syndrome (MetS)b, n (%) 72 35.6%
Number of MetS componentsb
0 27 13.4%
1 41 20.3%
2 62 30.7%
3 41 20.3%
4 21 10.4%
5 10 5.0%
Factor of global ability g, mean ± SD −0.06 ± 1.01
Mini Mental State Examination (MMSE)a, median (interquartile range) 29 (28–30)
MMSE< 27a, n (%) 12 6.0%
afor HbA1c, N = 155; for total cholesterol, N = 158; for LDL-C, N = 157; for MMSE, N = 200
bfor definition, see Table 1
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(60.9%) and elevated fasting glucose (61.9%) respectively
(Table 1). Obesity was present in 22.3%, TG were ele-
vated in 29.7%, and HDL-C was reduced in 34.2% of par-
ticipants. Seventy-two participants (35.6%) fulfilled the
criteria for MetS.
Comparison of Mini-Mental State Examination (MMSE)
scores across tertiles of g
Scores on the MMSE differed statistically significantly
across tertiles of g (F (2, 197) = 12.38; p < 0.001; ŋp2 = 0.11).
Participants with cognitive impairment (those scoring in
the lowest tertile g) had lower MMSE (geometric mean
28.1, 95% CI 27.8, 28.4) relative to the second (geometric
mean 28.7, 95% CI 28.4, 29.0) and third tertiles (geometric
mean 29.1, 95% CI 28.8, 29.4) (pairwise comparison
range p < 0.001 to p = 0.110). Of 12 participants with
MMSE< 27, 8 had cognitive impairment when defined
from g (chi2 (1, N = 200) = 5.42; p = 0.020).
Age- and sex associations with cognitive impairment
Age was directly associated with cognitive impairment.
Each 5-year increase in age was associated with a 1.79-fold
increased odds of impairment (OR 1.79 per 5-year incre-
ment, 95% CI 1.30, 2.47; p < 0.001). Sex was unrelated to
impairment in the same model (male versus female, OR
0.70, 95% CI 0.38, 1.28; p = 0.25).
Continuous metabolic parameters and odds of cognitive
impairment
The odds of cognitive impairment according to each of
the continuous metabolic parameters and their quartiles
are shown in Table 3. HDL-C quartiles were significantly
associated with cognitive impairment (ptrend across quar-
tiles adjusted for age, sex, smoking = 0.004). Thus, per-
sons in the highest versus lowest quartile of HDL-C had
a 0.28-fold odds (95% CI 0.11–0.71). The association
also survived addition of BMI, TG, glucose, CHD, TIA
and stroke into the model (ptrend across quartiles =
0.023). On a continuous scale, in the fully adjusted
model, each 1 unit mmol/L higher HDL-C concentration
was associated with a 0.39-fold odds (OR 0.39; 95% CI
0.16, 0.94; p = 0.036) of cognitive impairment.
Higher glucose levels were also related to a higher
odds of cognitive impairment in the fully adjusted model
(ptrend across quartiles = 0.045). On a continuous scale, 1
mmol/L higher glucose levels were associated with a sta-
tistically non-significant trend for a 1.21-fold odds
(95%-CI 0.97–1.51; p = 0.086) of cognitive impairment.
BMI, TG levels, and HbA1c concentrations were not
substantially related to cognitive impairment in these
analyses. To test for non-linearity we added quadratic
terms of the metabolic parameters to each of the fully
adjusted models; however, none of these quadratic terms
were statistically significant (HDL-C, p = 0.407; TG, p =
0.556; BMI, p = 0.788; glucose, p = 0.282; HbA1c, p =
0.849), suggesting that non-linear models did not im-
prove model fit.
Metabolic syndrome, the 5 MetS components and odds
of cognitive impairment
Participants with elevated TG were at 2.09-fold odds of
cognitive impairment in analyses controlling for age, sex
and smoking (OR 2.09, 95% CI 1.08, 4.05, p = 0.028) and
when obesity, reduced HDL-C, elevated glucose and ele-
vated BP were additionally adjusted for (OR 2.23, 95%
CI 1.07, 4.65, p = 0.033; Table 4). Addition of CHD, TIA
and stroke into the model led to statistically
non-significant results, however (OR 1.86; 95% CI 0.87,
4.00; p = 0.110). Obesity, reduced HDL-C, elevated
glucose and elevated BP were each not associated with
cognitive impairment (all p > 0.05; see Table 4). The
presence of MetS was not significantly related to
cognitive impairment (OR adjusted for age, sex, smoking
1.38; 95% CI 0.74, 2.60; p = 0.310; Table 4). The number
of MetS components was also not significantly
associated with impairment (OR per number of compo-
nent increment, adjusted for age, sex, smoking, 1.16,
95% CI 0.92, 1.45; p = 0.212; Table 5). Pairwise compari-
son showed a lower odds of cognitive impairment in the
group with 1 MetS component compared with the refer-
ence group with 0 components in the fully adjusted
model (OR 0.29; 95% CI 0.09, 0.95; p = 0.041) though no
significant differences in the odds of cognitive impair-
ment in participants with 2, 3 or 4/5 MetS components
compared with the reference group were found (all p >
0.05; Table 5).
Discussion
In this cross-sectional analysis of a sample of older sur-
gical patients without clinical dementia, participants
with lower HDL cholesterol (HDL-C) and those with el-
evated triglycerides (TG) were at increased likelihood of
being cognitively impaired. Individuals with higher glu-
cose levels also had a higher odds of cognitive impair-
ment, although these results became apparent only in
quartile analyses. Importantly, the associations for
HDL-C and glucose, but not for elevated TG, were
largely independent of one another, of other parameters
of metabolic dysfunction, and of age, sex, smoking and a
history of macrovascular disease. Obesity and elevated
blood pressure were not substantially associated with
cognitive impairment.
Associations of mid-life obesity [8], mid-life dyslipidemia
[20, 21] and mid-life hypertension [22] with later cognitive
impairment including increased risk of Alzheimer’s disease
and presence of Alzheimer’s-type neuropathology [23, 24]
are well-established. In later life, these risk factors are
more difficult to evaluate partly due to an influence of
Feinkohl et al. BMC Geriatrics           (2019) 19:77 Page 5 of 11
frailty [25], and previous studies of dyslipidemia in older
age and cognitive impairment have produced mixed re-
sults. Null findings for diagnosed dyslipidemia [26] and for
levels of total cholesterol [9], HDL-C [27] and TG [27, 28]
are contrasted with studies showing an increased risk of
cognitive impairment in people with low HDL-C [29, 30]
or elevated TG in later life [31, 32]. Here, our data suggest
a contribution of low HDL-C to cognitive impairment that
Table 3 Odds of cognitive impairment according to continuous metabolic parameters
Quartiles ptrend Continuous parameters
1 2 3 4 OR (95% CI) per unit increment p-value
Body mass index
Cut-point (kg/m2) ≤24.15 24.16–26.70 26.71–29.35 ≥29.36
n with cognitive
impairment / N total
19 / 51 18 / 51 18 / 50 17 / 50
Model 1 OR (95% CI) 1.00 (Reference) 0.96 (0.41, 2.25) 1.17 (0.50, 2.75) 1.02 (0.43, 2.41) 0.971 0.99 (0.92, 1.06) 0.772
Model 2 OR (95% CI) 1.00 (Reference) 1.06 (0.41, 2.70) 1.11 (0.43, 2.87) 0.64 (0.23, 1.80) 0.707 0.95 (0.88, 1.03) 0.205
Model 3 OR (95% CI) 1.00 (Reference) 0.98 (0.37, 2.64) 1.18 (0.44, 3.13) 0.59 (0.20, 1.75) 0.602 0.95 (0.88, 1.03) 0.238
Triglycerides
Cut-point (mmol/L) ≤1.04 1.05–1.31 1.32–1.79 ≥1.80
n with cognitive
impairment / N total
17 / 53 14 / 49 23 / 50 18 / 50
Model 1 OR (95% CI)a 1.00 (Reference) 0.92 (0.38, 2.24) 2.20 (0.94, 5.19) 1.58 (0.66, 3.77) 0.167 1.11 (0.93, 1.32) 0.241
Model 2 OR (95% CI)a 1.00 (Reference) 1.07 (0.39, 2.91) 2.22 (0.82, 5.98) 0.91 (0.31, 2.73) 0.259 1.02 (0.88, 1.18) 0.835
Model 3 OR (95% CI)a 1.00 (Reference) 1.08 (0.38, 3.07) 2.08 (0.75, 5.76) 0.73 (0.23, 2.31) 0.237 1.02 (0.88, 1.18) 0.791
High-density lipoprotein cholesterol
Cut-point (mmol/L) ≤1.01 1.02–1.27 1.28–1.55 ≥1.56
n with cognitive
impairment / N total
28 / 54 10 / 52 21 / 52 13 / 44
Model 1 OR (95% CI) 1.00 (Reference) 0.23 (0.09, 0.57) 0.65 (0.29, 1.48) 0.28 (0.11, 0.71) 0.004 0.37 (0.18, 0.80) 0.011
Model 2 OR (95% CI) 1.00 (Reference) 0.25 (0.09, 0.65) 0.57 (0.22, 1.44) 0.26 (0.09, 0.80) 0.017 0.39 (0.17, 0.92) 0.031
Model 3 OR (95% CI) 1.00 (Reference) 0.28 (0.10, 0.75) 0.53 (0.20, 1.41) 0.22 (0.07, 0.70) 0.023 0.39 (0.16, 0.94) 0.036
Glucose
Cut-point (mmol/L) ≤5.27 5.28–5.77 5.78–6.49 ≥6.50
n with cognitive impairment
/ N total
21 / 54 14 / 48 14 / 52 23 / 48
Model 1 OR (95% CI) 1.00 (Reference) 0.56 (0.23, 1.35) 0.56 (0.24, 1.33) 1.62 (0.71, 3.70) 0.053 1.19 (0.99, 1.43) 0.068
Model 2 OR (95% CI) 1.00 (Reference) 0.66 (0.26, 1.66) 0.42 (0.16, 1.10) 1.58 (0.61, 4.08) 0.062 1.19 (0.97, 1.46) 0.094
Model 3 OR (95% CI) 1.00 (Reference) 0.62 (0.23, 1.66) 0.45 (0.16, 1.21) 1.84 (0.69, 4.91) 0.045 1.21 (0.97, 1.51) 0.086
HbA1c
Cut-point (mmol/mol) ≤35.5 35.6–38.8 38.9–42.1 ≥42.2
n with cognitive
impairment / N total
15 / 46 14 / 37 12 / 38 17 / 34
Model 1 OR (95% CI) 1.00 (Reference) 1.26 (0.49, 3.27) 0.65 (0.24, 1.75) 2.15 (0.83, 5.54) 0.142 1.03 (0.99, 1.08) 0.137
Model 2 OR (95% CI) 1.00 (Reference) 1.24 (0.44, 3.46) 0.54 (0.18, 1.63) 1.71 (0.61, 4.80) 0.235 1.03 (0.99, 1.08)b 0.137
Model 3 OR (95% CI) 1.00 (Reference) 0.75 (0.24, 2.39) 0.55 (0.18, 1.73) 1.47 (0.49, 4.36) 0.420 1.04 (0.99, 1.09)b 0.115
Results shown for logistic regression analyses with outcome cognitive impairment. p-value for trend (2-sided) based on the respective median within quartiles,
used as a continuous variable, and analyzed using the Wald chi2 statistic. CI, confidence interval; OR, odds ratio
aresults largely unchanged following exclusion of N = 1 outlier with high TG levels (28.9 mmol/L)
bin these models, HDL-C was significantly associated with cognitive impairment (Model 2: OR 0.27, 95% CI 0.09, 0.79, p = 0.016; Model 3: OR 0.28, 95% CI 0.09,
0.83, p = 0.022; for TG and BMI, all p > 0.05 in these models)
Model 1: adjusted for age, sex, smoking
Model 2: Model 1 + TG quartiles, HDL-C quartiles, BMI quartiles, glucose quartiles (for quartile analyses) or Model 1 + TG, HDL-C, BMI and glucose (for continuous
parameters) (analysis N = 202), or for HbA1c: Model 1 + TG quartiles, HDL-C quartiles, BMI quartiles (for HbA1c quartile analyses) or Model 1 + TG, HDL-C and BMI
(for analysis of HbA1c as continuous parameter) (analysis N = 155)
Model 3: Model 2 + CHD, TIA, stroke
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could indicate a causal relationship. Indeed, HDL-C has
vasoprotective and anti-inflammatory properties [33] so
that reduced inflammation could be a plausible mediator
of the association in our sample. TG levels correlate with
atherogenic and pro-inflammatory triglyceride-rich lipo-
proteins (TRL) [34] which may directly promote cognitive
impairment. Our findings also suggest a contribution of
macrovascular disease to the association of elevated TG
with cognitive impairment. Cerebrovascular disease
could be a mediator in the relationship, for instance. We
are unable to determine this from the present study.
Nonetheless, irrespective of the issue of causality and me-
diatory processes, elevated TG and HDL-C both appear to
be useful risk markers with potential for utility in clinical
settings and could contribute to screening tool
development.
The disparate findings on HDL-C as a continuous
metabolic parameter versus the dichotomized MetS
component ‘reduced HDL-C’ suggest that the latter
at-risk group may not necessarily be well-captured by
the standardized, sex-specific cut-off points that are cur-
rently in use [15]. Their reevaluation and update, includ-
ing determination whether sex-specific cut-offs are
necessary, may be warranted. We found no significant
association when we used TG as a continuous variable
or as quartiles in our analysis. In contrast, when based
on the standardized cut-off point [15], elevated TG were
significantly associated with cognitive impairment at
least in largely unadjusted analyses, suggesting that this
threshold is appropriate for cognitive risk prediction.
Nevertheless, given the relatively small sample size, the
results of our analysis need to be interpreted cautiously
and require replication in larger samples.
Previous epidemiological research has consistently im-
plicated hyperglycemia as detrimental to cognition. Irre-
spective of whether measured at midlife or later life,
diabetes, pre-diabetes [35–37], and poorer glycemic con-
trol in people with diabetes [37] have been linked to in-
creased risk of vascular-type impairment as well as
Alzheimer’s disease [38]. Neurotoxic effects of glucose
on the brain [39] and hyperglycemia-induced vascular
damage [40] which appear to generate vascular impair-
ment as well as facilitate neurodegeneration characteris-
tic of Alzheimer’s disease [41] have been suggested as
underlying the relationship. In our sample, we found evi-
dence for a more complex role of glucose in cognitive
impairment that became apparent only in quartile ana-
lyses and was not supported by analyses of HbA1c as an
index of long-term glycemic control. The marginally sig-
nificant result could thus reflect Type I error. The fact
Table 4 MetS, each of the 5 MetS components and odds of cognitive impairment
Model 1 Model 2 Model 3
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Metabolic syndrome 1.38 (0.74, 2.60) 0.310 – – 1.25 (0.65, 2.42) 0.503
Obesity 1.07 (0.52, 2.23) 0.852 1.00 (0.46, 2.17) 0.997 1.08 (0.48, 2.43) 0.845
Elevated triglycerides 2.09 (1.08, 4.05) 0.028 2.23 (1.07, 4.65) 0.033 1.86 (0.87, 4.00) 0.110
Reduced high-density lipoprotein 1.19 (0.63, 2.23) 0.600 0.86 (0.42, 1.77) 0.691 0.87 (0.41, 1.82) 0.704
Elevated blood pressure 1.11 (0.60, 2.07) 0.740 1.04 (0.54, 2.00) 0.911 0.86 (0.44, 1.71) 0.668
Elevated glucose 1.12 (0.60, 2.08) 0.721 0.98 (0.51, 1.88) 0.948 1.09 (0.55, 2.14) 0.811
Results shown for logistic regression analyses for odds of cognitive impairment. CI, confidence interval; OR, odds ratio. For definitions of metabolic syndrome
components, see Table 1. Model 1: separate models associated each exposure variable with cognitive impairment with adjustment for age, sex and smoking (N = 202).
Model 2: single model including age, sex, smoking, obesity, elevated TG, reduced HDL-C, elevated blood pressure, elevated glucose (N = 202). Model 3: single model
including age, sex, smoking, obesity, elevated TG, reduced HDL-C, elevated blood pressure, elevated glucose, CHD, TIA, stroke (N = 200). Model 3 is a separate model for
MetS. Results largely unchanged following exclusion of N = 1 outlier with high TG levels (28.9mmol/L)
Table 5 Number of MetS components and odds of cognitive impairment
Number of components Model 1 Model 2
OR (95% CI) p OR (95% CI) p
0 1.00 (Reference)a – 1.00 (Reference)b –
1 0.36 (0.11, 1.15)a 0.084 0.29 (0.09, 0.95)b 0.041
2 1.02 (0.38, 2.77)a 0.965 0.93 (0.34, 2.52)b 0.878
3 0.94 (0.32, 2.77)a 0.902 0.76 (0.26, 2.28)b 0.629
4/5c 1.23 (0.40, 3.77)a 0.713 0.99 (0.31, 3.12)b 0.982
Number of components (continuous)d 1.16 (0.92, 1.45) 0.212 1.11 (0.88, 1.41) 0.387
Model 1: adjusted for age, sex and smoking (N = 202). Model 2: adjusted for age, sex, smoking, CHD, TIA, stroke (N = 200)
asingle model; bsingle model
cdue to small N in each, groups with 4 or 5 components were merged in this analysis
drange 0 to 5
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that – for consistency with standard definitions of MetS
[15] – diagnosis of diabetes qualified for inclusion in the
‘elevated glucose’ group, may also have ‘diluted’ that
group leading to non-significant results. Alternatively,
the standardized cut-off point for ‘elevated glucose’ [15]
may not be appropriate for our sample of surgical pa-
tients who may have had extended periods of fasting
prior to blood collection or for whom fasting status may
not have been recorded with sufficient rigor. The high
prevalence of ‘elevated glucose’ (61.9%, albeit as afore-
mentioned this included participants with diabetes) sup-
ports the latter possibility. The precise role of glucose in
cognitive impairment thus remains to be explored
further.
The evidence for obesity in older age as a risk factor
for cognitive impairment is limited [8] with occasional
implication of overweight, obesity and elevated waist cir-
cumference as protective factors [29, 42, 43]. Here, obes-
ity and BMI both were not related to cognition. At the
lower end of the body weight spectrum, the relationship
may be affected by frailty [25] but results on obesity and
BMI did not change when underweight participants were
excluded from our analysis or when quadratic terms
were added into the model. Elevated blood pressure, too,
was unrelated to cognitive impairment contrasting with
some other cross-sectional and longitudinal studies of
older adults [22].
Previous studies of the MetS construct and cognitive
impairment have occasionally produced null results
similar to our own [44, 45]. However, others did report
associations with impairment [7, 29, 30, 46, 47]. For in-
stance, in the Singapore Longitudinal Ageing Study, par-
ticipants with MetS were at 1.46-fold increased risk of
mild cognitive impairment (MCI) during 6-year
follow-up [7]. In the French Three-City Study of more
than 7000 older adults, MetS – in line with its status as
a vascular risk factor – was selectively associated with a
2.42-fold increased risk of impairment of vascular origin
[29]. Finally, women with MetS were at 2.47-fold in-
creased risk of poor memory 12 years later in a Finnish
investigation [30] and a pooled analysis of three studies
reported that MetS was overall associated with 2.95-fold
increased risk of progression from MCI to dementia
[48]. The Finnish study [30] and some others [49] add-
itionally reported a linear relationship of the number of
MetS components with cognitive risk, but we and others
[29, 47] found no such evidence. Disparity of our results
from previous studies could stem from our slightly modi-
fied definition of MetS, the cross-sectional study design,
the surgical nature of our sample, and the high prevalence
of MetS (35.6%) compared with those studies (12.9% [30];
15.8% [29]; 22.4% [7]) but is in line with a recent system-
atic review of 25 studies which concluded that the evi-
dence on associations of MetS with cognitive impairment
in older age is insufficient at present [49]. A recent report
of accumulation of beta amyloid in the brains of people
with MetS [50] demonstrate the need for further research
into the cognitive and neuropathological consequences of
the syndrome.
Each MetS component (except obesity) can be
modified through pharmaceutical treatment and the
potential benefit of concurrent tackling of several com-
ponents is being increasingly recognized. Thus, the
ACCORD-MIND trial recently tested the effect of anti-
diabetic, lipid lowering and blood pressure lowering
therapy, in a double 2 × 2 factorial design; however, nei-
ther improved glycemic control [51], nor improved lipid
levels or blood pressure [52] affected the rate of cogni-
tive decline during 40-month follow-up, suggesting that
the epidemiological evidence linking elevated glucose,
dyslipidemia and elevated blood pressure to cognitive
impairment may be confounded. Further similarly com-
plex trials are needed for clarification of the effects of
strategic targeting of different metabolic parameters, as
well as benefits of concurrent treatment, on cognitive
risk.
Strengths of our study include a multi-center design
and the use of a comprehensive cognitive test battery
that was validated through comparison with an instru-
ment commonly used to assess cognitive status. Consid-
eration of several metabolic parameters in a single
analysis was able to evaluate relative independence of
each from one another in their relationship with cogni-
tion. Thus far the 5 MetS components have mainly been
investigated in isolation. Only a few studies directly
compared the components in terms of their association
with cognitive risk and had implicated low HDL-C [30],
elevated TG [29], hypertension [46] and, most fre-
quently, hyperglycemia [26, 44] as independent risk
markers. However, some limitations need to be consid-
ered. Surgical patients are at risk of developing
post-operative cognitive impairment [53] and so are of
special interest in terms of their cognitive status. To our
knowledge the present study is the first to assess MetS
and cognitive impairment in this type of sample. At the
same time, the focus on surgical patients as well as
self-selection bias preventing unwell patients to enroll
limits the generalizability of our findings to the general
population that includes healthy, community-dwelling
individuals. Further, we used BMI as a proxy for central
obesity [12] though strictly speaking central obesity can
only be determined through direct measurement. We
also did not consider MetS-related complications such
as retinopathy in our analysis. The possibility of con-
founding of our statistically significant findings by un-
measured factors such as diet or physical activity, too,
remains. Because ‘cognitive impairment’ was defined
from a cognitive summary score, our results are not
Feinkohl et al. BMC Geriatrics           (2019) 19:77 Page 8 of 11
necessarily comparable to studies that used standardized
constructs such as MCI. Due to the cross-sectional study
design we were unable to evaluate participants’ metabolic
function during the decades prior to enrolment and did
not consider anti-hyperglycemic, anti-hypertensive and
lipid-lowering treatment in our analysis. Associations of
elevated blood pressure with cognitive impairment may
thus have become apparent had we controlled for or
stratified by treatment. We deem confounding of our find-
ings on HDL-C by anti-dyslipidemia drugs unlikely given
the balance of epidemiological and trial evidence which
suggests a limited role of drugs such as statins or fibrates
in cognitive decline [54–56]. In any event, the fact that we
observed associations of HDL-C with cognitive
impairment despite lacking data on treatment indicates
that the underlying processes may be mechanistic and
dose-dependent on lipid concentrations irrespective of
whether they are treated. Finally, our sample was relatively
small and so the fact that we did not find significant asso-
ciations for some of the MetS components does not rule
out that studies with larger sample size may be able to de-
tect smaller effects. Further prospective, epidemiological
studies comparing the contributions of each of the 5 com-
ponents to cognitive risk are needed and should take ad-
vantage of a range of different types of samples to gain a
full understanding of any sample-specific relationships of
MetS with cognitive impairment. Researchers should add-
itionally consider analysis of inflammatory markers, which
may interact with MetS in determining cognitive outcome
[57], as well as pre-morbid cognitive ability (which affects
both cognitive ability and metabolic risk in older age [58])
to explore mediation and confounding.
In conclusion, in this cross-sectional analysis of older
adults who were all free of clinical dementia and sched-
uled to undergo surgery, lower HDL-C and elevated TG
were each associated with presence of cognitive impair-
ment defined as reduced cognitive performance relative
to the total sample. For HDL-C, but not for elevated
TG, the finding was independent of age, sex, smoking,
the remaining parameters of metabolic dysfunction, as
well as of macrovascular disease. This suggests potential
for a causal relationship. The MetS construct per se was
not associated with cognition. Prospective studies should
compare the cognitive risk associated with different pa-
rameters of metabolic dysfunction in view to identify
at-risk individuals and to shed light on underlying
pathophysiological mechanisms considering that the evi-
dence for metabolic parameters as effective targets for
intervention is currently limited.
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